Stryker Co. (NYSE:SYK) Shares Purchased by Perkins Coie Trust Co

Perkins Coie Trust Co raised its stake in shares of Stryker Co. (NYSE:SYKFree Report) by 0.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 12,288 shares of the medical technology company’s stock after buying an additional 58 shares during the period. Perkins Coie Trust Co’s holdings in Stryker were worth $4,397,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Harbor Investment Advisory LLC increased its stake in shares of Stryker by 0.4% in the 1st quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock valued at $2,499,000 after acquiring an additional 31 shares during the last quarter. Bremer Bank National Association increased its stake in shares of Stryker by 4.0% in the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after acquiring an additional 34 shares during the last quarter. Simon Quick Advisors LLC grew its position in shares of Stryker by 3.0% in the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after purchasing an additional 34 shares during the period. Consolidated Portfolio Review Corp grew its position in shares of Stryker by 3.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 34 shares during the period. Finally, FourThought Financial Partners LLC grew its position in shares of Stryker by 3.3% in the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after purchasing an additional 34 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SYK. Needham & Company LLC upgraded Stryker from a “hold” rating to a “buy” rating and set a $392.00 price objective for the company in a research report on Wednesday, May 22nd. TD Cowen boosted their price objective on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Piper Sandler boosted their price objective on Stryker from $375.00 to $380.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Monday, June 17th. Finally, Citigroup upped their price target on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $370.58.

View Our Latest Analysis on Stryker

Stryker Stock Performance

SYK traded down $3.45 during trading hours on Monday, reaching $339.19. The company’s stock had a trading volume of 1,040,844 shares, compared to its average volume of 1,320,799. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $361.41. The company’s 50-day moving average is $336.69 and its 200-day moving average is $332.60. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. The firm has a market cap of $129.21 billion, a PE ratio of 38.72, a price-to-earnings-growth ratio of 2.69 and a beta of 0.92.

Stryker (NYSE:SYKGet Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The business had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.14 EPS. On average, equities analysts forecast that Stryker Co. will post 11.95 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be paid a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend is Friday, June 28th. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

About Stryker

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.